Business
Curatis: Sales growth of 30% in distribution - plus significant expansion of patient target group for lead project C-PTBE-01
LIESTAL, Switzerland, March 27, 2025--Curatis Holding AG (SIX:CURN, ‘Curatis’) reports business revenues of CHF 6.9m for 2024, whereby Curatis AG is only included for 8 months. Curatis AG was able to increase sales in the distribution business by 30% per cent to CHF 9.5m in the full year 2024 compared to 2023.
About this update from Curatis Holding Ag
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":2953,"height":827,"url":"https://media.zenfs.com/en/business-wire.com/09fd0f1a2d445c16fba275b73a2339f7"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/XT3FD4E9sDoyrLTF4GxtLw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTI2OTtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/09fd0f1a2d445c16fba275b73a2339f7","width":960,"height":269},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/XKb6SLH.cdGnDH.lGAIquw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD02NzI7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/09fd0f1a2d445c16fba275b73a2339f7","width":1200,"height":336}},"lazy":false},{"type":"text","content":"LIESTAL, Switzerland, March 27, 2025--(BUSINESS WIRE)--Curatis Holding AG (SIX:CURN, ‘Curatis’) reports business revenues of CHF 6.9m for 2024, whereby Curatis AG is only included for 8 months. Curatis AG was able to increase sales in the distribution business by 30% per cent to CHF 9.5m in the full year 2024 compared to 2023.","length":328,"tagName":"p"},{"type":"text","content":"Further key statements:","length":23,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Curatis is increasing the estimate for the number of patients addressed in the lead project C-PTBE-01 by a factor of 20.","length":120,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"The reason for this is that Curatis can apply for a biologics licence for C-PTBE-01, which grants 12 years of market protection in the USA. This suggests an expansion of the indications, namely from PTBE in diffuse midline glioma (DMG) in children to PTBE in other primary and metastatic brain tumours in children and adults.","length":325,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"A meeting with the US Food and Drug Administration (FDA) to discuss a potential pivotal Phase III trial for C-PTBE-01 is in preparation and is targeted for Q2.","length":159,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"The strong cash position of CHF 3m at the end of the year combined with the positive, growing cash flow from sales and the lean organisation provide a solid foundation for Curatis' operating activities.","length":206,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"len...